NeuroPhage Pharmaceuticals Obtains $10,000,000 Series D Round

  • Feed Type
  • Date
  • Company Name
    NeuroPhage Pharmaceuticals
  • Mailing Address
    222 3rd St. Cambridge, MA 02142 USA
  • Company Description
    NeuroPhage is developing a breakthrough protein dissaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer’s disease (AD) drug candidate, NPT001, safely and effectively dissaggregates existing Aß plaque in preclinical animal models, which is unique among disease-modifying approaches for AD.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds from the financing will be used to advance the Company’s lead drug candidate, NPT088, into clinical studies by the end of this year.
  • M&A Terms
  • Venture Investor

Trending on Xconomy